CSL Faces Shareholder Class Action Over Forecasts
Australian biotech firm CSL is facing a shareholder class action over alleged breaches of continuous disclosure rules regarding financial forecasts. The legal challenge follows profit warnings and impairment charges that have rattled investors over the past year.
Xurve View
Insights:
Xurve View
CSL LTD-SPONSORED ADR faces a shareholder class action in Australia over continuous disclosure breaches regarding its financial forecasts, sending shares down 1.1%. The legal challenge follows profit warnings, a delayed demerger, and a $5 billion impairment charge. Investors seek damages over retracted guidance issued between February 2025 and May 2026.
